A
Ariceum Therapeutics
Targeted radiopharmaceuticals for hard-to-treat cancers
About Ariceum Therapeutics
Ariceum Therapeutics is a biotechnology company that is focused on developing innovative treatments for cancer and other diseases. The company is dedicated to finding new ways to fight cancer and other diseases by combining cutting-edge technology and modern medicine. They use a combination of advanced analytics, data science, and machine learning to develop new treatments.
Read full description
Ariceum Therapeutics is different from other businesses in the same industry because of their use of advanced analytics, data science, and machine learning to develop new treatments. They use Google Analytics Cookies, other external services, Google Webfont Settings, Google Map Settings, Google reCaptcha Settings, Vimeo and Youtube video embeds to analyze and develop treatments.
Ariceum Therapeutics makes a profit by selling their treatments to medical professionals and healthcare organizations. They also generate revenue through grants and investments from investors.
The company is committed to providing innovative treatments that can improve the lives of patients and make a real difference in the fight against cancer and other diseases.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Berlin, Germany
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 27.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Radioisotope Therapeutics, Hard Tech, Radiopharmaceuticals, DT and LS, start2 group, German Accelerator, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jun 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Apr 2023 | $25M | $138M | Earlybird Venture Capital · Pureos Bioventures · Andera Partners | ↗ |
| SERIES AOther financing | Jun 2022 | $28M | $110M | EQT Life Sciences · HealthCap · EQT Group · Pureos Bioventures | ↗ |
Growth signals
Latest recorded traffic for Ariceum Therapeutics is 340 monthly website visits, up 30.8% over the last three months. Ariceum Therapeutics's team declined 34.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
EQT Life Sciences
HealthCap
EQT Group
Pureos Bioventures
Earlybird Venture Capital
Andera Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ariceum Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ariceum Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.